||

Update 22 5th April 2011

Update 22 5th April 2011

Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2011/2012 northern hemisphere season and the2011 southern hemisphere season. (See below for pricing information)

 

Update 22, 05 April 2011

 

Northern Hemisphere 2011/20122,3 and Southern Hemisphere 20111

Candidate influenza vaccine viruses

NIBSC code

H1N1

 

A/California/7/2009 wild type virus

10/122

NYMC X-179A reassortant derived from A/California/7/2009

09/216

NYMC X-181 reassortant derived from A/California/7/2009

09/314

IVR-153 reassortant derived from A/California/7/2009

09/236

NIBRG-121 reassortant derived from A/California/7/2009

09/122

NIBRG-121xp reassortant derived from A/California/7/2009

09/268

NIBRG-122 reassortant derived from A/England/195/2009

09/130

NIB-74 reassortant derived from A/Christchurch/16/2010 

(A/California/7/2009 – like)

 10/216

H3N2

 

A/Perth/16/2009 wild type virus

09/208

NIB-64 reassortant derived from A/Perth/16/2009

09/280

NYMC X-183 reassortant derived from A/Wisconsin/15/2009

09/248

 NYMC X-185 reassortant derived from A/Guangdong-Luohu/1256/2009

09/274

 NYMC X-187 reassortant derived from A/Victoria/210/2009

09/290

 NIB-65 reassortant derived from A/Victoria/210/2009

09/298

IVR-155 reassortant derived from A/Victoria/210/2009

09/304

B

 

B/Brisbane/60/2008

10/244

B/Brisbane/33/2008

08/280

NYMC BX-31 reassortant derived from B/Brisbane/60/2008

10/276

NIB-58 reassortant derived from B/Brisbane/60/2008

10/260

NYMC BX-35 reassortant derived from B/Brisbane/60/2008

09/318

 NYMC BX-39 reassortant derived from B/Hubei Wjiagang/158/2009  10/270

 

1 WHO | Recommended composition of influenza virus vaccines for use in the 2011 southern hemisphere influenza season

2 http://www.who.int/csr/disease/influenza/recommendations_2011_12north/en/index.html

3 http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/03/WC500103708.pdf

 

Reagents for influenza vaccine standardisation

NIBSC code

H1N1

 

A/California/7/2009 (NYMC X-179A) egg derived antigen

09/146

A/California/7/2009 (NYMC X-179A) cell derived antigen

09/174

A/California/7/2009 (NIBRG-121xp) egg derived antigen

09/196

  A/California/7/2009 (NYMC X-181)

09/294

 A/Christchurch/16/2010 (NIB-74)  10/258

A/California/7/2009 antiserum

10/230

H3N2

 

A/Perth/16/2009 like antigen A/Wisconsin/15/2009 (NYMC X-183)

09/310

A/Perth/16/2009 like antigen A/Victoria/210/2009 (NYMC X-187)

10/102

A/Perth/16/2009 like antiserum

10/182

B

 

B/Brisbane/60/2008 antigen

08/352

B/Brisbane/60/2008 like antigen (NYMC BX-35)

10/106

B/Brisbane/60/2008 like antiserum

10/146

 

Neuraminidase reagents

NIBSC code

N1

 

Antiserum prepared from A/California/7/2009  10/218

antiserum prepared from A/New Caledonia/20/99

04/230

N2

 

antiserum prepared from A/Wyoming/3/2003

04/258

B

 

NA antiserum prepared from B/Jiangsu/10/2003

04/228

NA antiserum prepared from B/Malaysia/2506/2004

05/252

NA antiserum prepared for B/Florida/4/2006

09/316

 

 

Pricing information

Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to the usual NIBSC handling charge of £63 per vial, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the £63 handling fee.